Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy

L. Lit, Frank R Sharp, Michelle L Apperson, Da Liu, W. L. Walker, I. Liao, H. Xu, Bradley Ander, B. Wong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents nave to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.

Original languageEnglish (US)
Pages (from-to)411-418
Number of pages8
JournalPharmacogenomics Journal
Volume9
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Duchenne Muscular Dystrophy
Adrenal Cortex Hormones
Gene Expression
Prednisone
Chondroitin Sulfates
Genes
Iron
Messenger RNA
deflazacort

Keywords

  • Corticosteroid
  • Duchenne muscular dystrophy
  • Gene expression
  • Microarray
  • Prednisone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy. / Lit, L.; Sharp, Frank R; Apperson, Michelle L; Liu, Da; Walker, W. L.; Liao, I.; Xu, H.; Ander, Bradley; Wong, B.

In: Pharmacogenomics Journal, Vol. 9, No. 6, 12.2009, p. 411-418.

Research output: Contribution to journalArticle

@article{283334026e4d4405a4c0074016c9da8c,
title = "Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy",
abstract = "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents nave to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.",
keywords = "Corticosteroid, Duchenne muscular dystrophy, Gene expression, Microarray, Prednisone",
author = "L. Lit and Sharp, {Frank R} and Apperson, {Michelle L} and Da Liu and Walker, {W. L.} and I. Liao and H. Xu and Bradley Ander and B. Wong",
year = "2009",
month = "12",
doi = "10.1038/tpj.2009.22",
language = "English (US)",
volume = "9",
pages = "411--418",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy

AU - Lit, L.

AU - Sharp, Frank R

AU - Apperson, Michelle L

AU - Liu, Da

AU - Walker, W. L.

AU - Liao, I.

AU - Xu, H.

AU - Ander, Bradley

AU - Wong, B.

PY - 2009/12

Y1 - 2009/12

N2 - Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents nave to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.

AB - Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents nave to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.

KW - Corticosteroid

KW - Duchenne muscular dystrophy

KW - Gene expression

KW - Microarray

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=73949133918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949133918&partnerID=8YFLogxK

U2 - 10.1038/tpj.2009.22

DO - 10.1038/tpj.2009.22

M3 - Article

C2 - 19488064

AN - SCOPUS:73949133918

VL - 9

SP - 411

EP - 418

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 6

ER -